Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome

Pharyngeal-cervical-brachial (PCB) variant of Guillain-Barré syndrome (GBS) is a rare regional variant of GBS characterized by rapidly progressive weakness predominantly affecting the pharyngeal (throat), cervical (neck), and brachial (arm and shoulder) muscles. It is an acute immune-mediated polyneuropathy that primarily targets the peripheral nerves supplying these regions. The condition is sometimes referred to as a 'descending' form of GBS because weakness typically begins in the oropharyngeal and neck muscles before spreading to the upper limbs, while the lower limbs are relatively spared or only mildly affected. Like other forms of GBS, it is often preceded by an infectious illness, most commonly a respiratory or gastrointestinal infection, occurring days to weeks before neurological symptom onset. Key clinical features include dysphagia (difficulty swallowing), dysarthria (slurred speech), facial weakness, neck flexor and extensor weakness, and proximal upper limb weakness. Deep tendon reflexes are typically reduced or absent in the upper limbs. Some patients may also develop mild lower limb weakness or sensory symptoms. The condition can be confused with other disorders such as myasthenia gravis, brainstem stroke, or botulism due to the prominent bulbar involvement. Anti-GT1a and anti-GQ1b ganglioside antibodies are frequently detected in patients with the PCB variant and can aid in diagnosis. Electrodiagnostic studies typically show features of a demyelinating or axonal neuropathy predominantly affecting the cranial and upper limb nerves. Treatment follows the same approach as classic GBS and includes intravenous immunoglobulin (IVIg) or plasma exchange (plasmapheresis) as first-line immunomodulatory therapies. Supportive care is essential, particularly monitoring for respiratory compromise due to pharyngeal and respiratory muscle weakness, which may necessitate intubation and mechanical ventilation in severe cases. The prognosis is generally favorable, with most patients achieving significant or complete recovery over weeks to months, although some may experience residual deficits. Early recognition and treatment are important to optimize outcomes.

Common questions about Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome